{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T11:29:03Z","timestamp":1790422143431,"version":"4.1.0"},"reference-count":135,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T00:00:00Z","timestamp":1626739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Given the absence of an effective vaccine for protection against HIV-1 infection, passive immunization strategies that utilize potent broadly neutralizing antibodies (bnAbs) to block acquisition of HIV-1 are being rigorously pursued in the clinical setting. bnAbs have demonstrated robust protection in preclinical animal models, and several leading bnAb candidates have shown favorable safety and pharmacokinetic profiles when tested individually or in combinations in early phase human clinical trials. Furthermore, passive administration of bnAbs in HIV-1 infected individuals has resulted in prolonged suppression of viral rebound following interruption of combination antiretroviral therapy, and robust antiviral activity when administered to viremic individuals. Recent results from the first efficacy trials testing repeated intravenous administrations of the anti-CD4 binding site bnAb VRC01 have demonstrated positive proof of concept that bnAb passive immunization can confer protection against HIV-1 infection in humans, but have also highlighted the considerable barriers that remain for such strategies to effectively contribute to control of the epidemic. In this review, we discuss the current status of clinical studies evaluating bnAbs for HIV-1 prevention, highlight lessons learned from the recent Antibody Mediated Prevention (AMP) efficacy trials, and provide an overview of strategies being employed to improve the breadth, potency, and durability of antiviral protection.<\/jats:p>","DOI":"10.3389\/fimmu.2021.712122","type":"journal-article","created":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T11:59:45Z","timestamp":1626782385000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":82,"title":["Broadly Neutralizing Antibodies for HIV-1 Prevention"],"prefix":"10.3389","volume":"12","author":[{"given":"Stephen R.","family":"Walsh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Seaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,7,20]]},"reference":[{"key":"B1","volume-title":"Data and Statistics","year":"2020"},{"key":"B2","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/nrmicro974","article-title":"Passive Antibody Therapy for Infectious Diseases","volume":"2","author":"Casadevall","year":"2004","journal-title":"Nat Rev Microbiol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000154","article-title":"History of Passive Antibody Administration for Prevention and Treatment of Infectious Diseases","volume":"10","author":"Graham","year":"2015","journal-title":"Curr Opin HIV AIDS"},{"key":"B4","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/nri.2017.148","article-title":"Passive Immunotherapy of Viral Infections: \u2018Super-Antibodies\u2019 Enter the Fray","volume":"18","author":"Walker","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1089\/mab.2021.0004","article-title":"Antibody Therapy: From Diphtheria to Cancer, COVID-19, and Beyond","volume":"40","author":"Kumar","year":"2021","journal-title":"Monoclon Antib Immunodiagn Immunother"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01340-07","article-title":"Adjunctive Passive Immunotherapy in Human Immunodeficiency Virus Type 1-Infected Individuals Treated With Antiviral Therapy During Acute and Early Infection","volume":"81","author":"Mehandru","year":"2007","journal-title":"J Virol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/nm1244","article-title":"Delay of HIV-1 Rebound After Cessation of Antiretroviral Therapy Through Passive Transfer of Human Neutralizing Antibodies","volume":"11","author":"Trkola","year":"2005","journal-title":"Nat Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.16.10103-10107.2005","article-title":"Recommendations for the Design and Use of Standard Virus Panels to Assess Neutralizing Antibody Responses Elicited by Candidate Human Immunodeficiency Virus Type 1 Vaccines","volume":"79","author":"Mascola","year":"2005","journal-title":"J Virol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2013.11.022","article-title":"Optimization and Validation of the TZM-Bl Assay for Standardized Assessments of Neutralizing Antibodies Against HIV-1","volume":"409","author":"Sarzotti-Kelsoe","year":"2014","journal-title":"J Immunol Methods"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01482-09","article-title":"Breadth of Human Immunodeficiency Virus-Specific Neutralizing Activity in Sera: Clustering Analysis and Association With Clinical Variables","volume":"84","author":"Doria-Rose","year":"2010","journal-title":"J Virol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/nm1624","article-title":"Broad HIV-1 Neutralization Mediated by CD4-Binding Site Antibodies","volume":"13","author":"Li","year":"2007","journal-title":"Nat Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02036-08","article-title":"Factors Associated With the Development of Cross-Reactive Neutralizing Antibodies During Human Immunodeficiency Virus Type 1 Infection","volume":"83","author":"Sather","year":"2009","journal-title":"J Virol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00110-09","article-title":"Human Immunodeficiency Virus Type 1 Elite Neutralizers: Individuals With Broad and Potent Neutralizing Activity Identified by Using a High-Throughput Neutralization Assay Together With an Analytical Selection Algorithm","volume":"83","author":"Simek","year":"2009","journal-title":"J Virol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2008.11.012","article-title":"A Method for Identification of HIV Gp140 Binding Memory B Cells in Human Blood","volume":"343","author":"Scheid","year":"2009","journal-title":"J Immunol Methods"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e8805","DOI":"10.1371\/journal.pone.0008805","article-title":"Analysis of Memory B Cell Responses and Isolation of Novel Monoclonal Antibodies With Neutralizing Breadth From HIV-1-Infected Individuals","volume":"5","author":"Corti","year":"2010","journal-title":"PloS One"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e24078","DOI":"10.1371\/journal.pone.0024078","article-title":"Memory B Cell Antibodies to HIV-1 Gp140 Cloned From Individuals Infected With Clade A and B Viruses","volume":"6","author":"Mouquet","year":"2011","journal-title":"PloS One"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nature07930","article-title":"Broad Diversity of Neutralizing Antibodies Isolated From Memory B Cells in HIV-Infected Individuals","volume":"458","author":"Scheid","year":"2009","journal-title":"Nature"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/nature10373","article-title":"Broad Neutralization Coverage of HIV by Multiple Highly Potent Antibodies","volume":"477","author":"Walker","year":"2011","journal-title":"Nature"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1126\/science.1178746","article-title":"Broad and Potent Neutralizing Antibodies From an African Donor Reveal a New HIV-1 Vaccine Target","volume":"326","author":"Walker","year":"2009","journal-title":"Science"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1126\/science.1187659","article-title":"Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1","volume":"329","author":"Wu","year":"2010","journal-title":"Science"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1126\/science.1207227","article-title":"Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding","volume":"333","author":"Scheid","year":"2011","journal-title":"Science"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-018-0235-7","article-title":"Recent Progress in Broadly Neutralizing Antibodies to HIV","volume":"19","author":"Sok","year":"2018","journal-title":"Nat Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2012.08.012","article-title":"Human Antibodies That Neutralize HIV-1: Identification, Structures, and B Cell Ontogenies","volume":"37","author":"Kwong","year":"2012","journal-title":"Immunity"},{"key":"B24","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12977-020-00516-2","article-title":"Benefits and Limitations of Humanized Mice in HIV Persistence Studies","volume":"17","author":"Marsden","year":"2020","journal-title":"Retrovirology"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiw203","article-title":"Protection of Humanized Mice From Repeated Intravaginal HIV Challenge by Passive Immunization: A Model for Studying the Efficacy of Neutralizing Antibodies In Vivo","volume":"214","author":"Deruaz","year":"2016","journal-title":"J Infect Dis"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s00705-016-2942-4","article-title":"VRC01 Antibody Protects Against Vaginal and Rectal Transmission of Human Immunodeficiency Virus 1 in Hu-BLT Mice","volume":"161","author":"Sun","year":"2016","journal-title":"Arch Virol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/nature11604","article-title":"HIV Therapy by a Combination of Broadly Neutralizing Antibodies in Humanized Mice","volume":"492","author":"Klein","year":"2012","journal-title":"Nature"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2014.05.036","article-title":"Efficacy of Broadly Neutralizing Monoclonal Antibody PG16 in HIV-Infected Humanized Mice","author":"Stoddart","year":"2014","journal-title":"Virology"},{"key":"B29","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12977-018-0449-7","article-title":"Adeno-Associated Virus Gene Delivery of Broadly Neutralizing Antibodies as Prevention and Therapy Against HIV-1","volume":"15","author":"Lin","year":"2018","journal-title":"Retrovirology"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2015.0258","article-title":"Improvements and Limitations of Humanized Mouse Models for HIV Research: NIH\/NIAID \u201cMeet the Experts\u201d 2015 Workshop Summary","volume":"32","author":"Akkina","year":"2016","journal-title":"AIDS Res Hum Retroviruses"},{"key":"B31","doi-asserted-by":"publisher","first-page":"3195","DOI":"10.1038\/s41467-020-16928-9","article-title":"Durable Protection Against Repeated Penile Exposures to Simian-Human Immunodeficiency Virus by Broadly Neutralizing Antibodies","volume":"11","author":"Garber","year":"2020","journal-title":"Nat Commun"},{"key":"B32","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.chom.2019.08.014","article-title":"A Meta-Analysis of Passive Immunization Studies Shows That Serum-Neutralizing Antibody Titer Associates With Protection Against SHIV Challenge","volume":"26","author":"Pegu","year":"2019","journal-title":"Cell Host Microbe"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/nature17677","article-title":"A Single Injection of Anti-HIV-1 Antibodies Protects Against Repeated SHIV Challenges","volume":"533","author":"Gautam","year":"2016","journal-title":"Nature"},{"key":"B34","doi-asserted-by":"publisher","first-page":"243ra288","DOI":"10.1126\/scitranslmed.3008992","article-title":"Neutralizing Antibodies to HIV-1 Envelope Protect More Effectively In Vivo Than Those to the CD4 Receptor","volume":"6","author":"Pegu","year":"2014","journal-title":"Sci Transl Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20132494","article-title":"Passive Transfer of Modest Titers of Potent and Broadly Neutralizing Anti-HIV Monoclonal Antibodies Block SHIV Infection in Macaques","volume":"211","author":"Shingai","year":"2014","journal-title":"J Exp Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01187-17","article-title":"Protective Efficacy of Broadly Neutralizing Antibodies With Incomplete Neutralization Activity Against Simian-Human Immunodeficiency Virus in Rhesus Monkeys","volume":"91","author":"Julg","year":"2017","journal-title":"J Virol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"eaal1321","DOI":"10.1126\/scitranslmed.aal1321","article-title":"Broadly Neutralizing Antibodies Targeting the HIV-1 Envelope V2 Apex Confer Protection Against a Clade C SHIV Challenge","volume":"9","author":"Julg","year":"2017","journal-title":"Sci Transl Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1214785109","article-title":"Highly Potent HIV-Specific Antibody Neutralization In Vitro Translates Into Effective Protection Against Mucosal SHIV Challenge In Vivo","volume":"109","author":"Moldt","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"B39","doi-asserted-by":"publisher","first-page":"eaao4235","DOI":"10.1126\/scitranslmed.aao4235","article-title":"Protection Against a Mixed SHIV Challenge by a Broadly Neutralizing Antibody Cocktail","volume":"9","author":"Julg","year":"2017","journal-title":"Sci Transl Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000298","article-title":"Estimating Per-Act HIV Transmission Risk: A Systematic Review","volume":"28","author":"Patel","year":"2014","journal-title":"AIDS"},{"key":"B41","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/imr.12511","article-title":"Use of Broadly Neutralizing Antibodies for HIV-1 Prevention","volume":"275","author":"Pegu","year":"2017","journal-title":"Immunol Rev"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00697","article-title":"Mind the Gap: How Interspecies Variability in IgG and Its Receptors May Complicate Comparisons of Human and Non-Human Primate Effector Function","volume":"10","author":"Crowley","year":"2019","journal-title":"Front Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000311","article-title":"Nonhuman Primate Models for the Evaluation of HIV-1 Preventive Vaccine Strategies: Model Parameter Considerations and Consequences","volume":"11","author":"Del Prete","year":"2016","journal-title":"Curr Opin HIV AIDS"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.03279-14","article-title":"Generation and Evaluation of Clade C Simian-Human Immunodeficiency Virus Challenge Stocks","volume":"89","author":"Chang","year":"2015","journal-title":"J Virol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1101\/2021.01.13.426578","article-title":"New SHIVs and Improved Design Strategy for Modeling HIV-1 Transmission, Immunopathogenesis, Prevention and Cure","volume":"95","author":"Li","year":"2021","journal-title":"J Virol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"e1007632","DOI":"10.1371\/journal.ppat.1007632","article-title":"Rational Design and In Vivo Selection of SHIVs Encoding Transmitted\/Founder Subtype C HIV-1 Envelopes","volume":"15","author":"O\u2019Brien","year":"2019","journal-title":"PloS Pathog"},{"key":"B47","doi-asserted-by":"publisher","first-page":"e1005431","DOI":"10.1371\/journal.ppat.1005431","article-title":"Production of Mucosally Transmissible SHIV Challenge Stocks From HIV-1 Circulating Recombinant Form 01_AE Env Sequences","volume":"12","author":"Tartaglia","year":"2016","journal-title":"PloS Pathog"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000638","article-title":"Recent Insights Into Fc-Mediated Effector Responses to HIV-1","volume":"15","author":"Carpenter","year":"2020","journal-title":"Curr Opin HIV AIDS"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000644","article-title":"Roles of Fragment Crystallizable-Mediated Effector Functions in Broadly Neutralizing Antibody Activity Against HIV","volume":"15","author":"Danesh","year":"2020","journal-title":"Curr Opin HIV AIDS"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02968","article-title":"Update on Fc-Mediated Antibody Functions Against HIV-1 Beyond Neutralization","volume":"10","author":"Su","year":"2019","journal-title":"Front Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1126\/science.aag0491","article-title":"Antibody-Mediated Protection Against SHIV Challenge Includes Systemic Clearance of Distal Virus","volume":"353","author":"Liu","year":"2016","journal-title":"Science"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf1279","article-title":"Enhanced Clearance of HIV-1-Infected Cells by Broadly Neutralizing Antibodies Against HIV-1 In Vivo","volume":"352","author":"Lu","year":"2016","journal-title":"Science"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/nature06106","article-title":"Fc Receptor But Not Complement Binding is Important in Antibody Protection Against HIV","volume":"449","author":"Hessell","year":"2007","journal-title":"Nature"},{"key":"B54","doi-asserted-by":"publisher","first-page":"eabe3349","DOI":"10.1126\/scitranslmed.abe3349","article-title":"Effector Function Does Not Contribute to Protection From Virus Challenge by a Highly Potent HIV Broadly Neutralizing Antibody in Nonhuman Primates","volume":"13","author":"Hangartner","year":"2021","journal-title":"Sci Transl Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1172\/JCI122466","article-title":"Fc-Dependent Functions are Redundant to Efficacy of Anti-HIV Antibody PGT121 in Macaques","volume":"129","author":"Parsons","year":"2019","journal-title":"J Clin Invest"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2008190117","article-title":"Quantifying the Contribution of Fc-Mediated Effector Functions to the Antiviral Activity of Anti-HIV-1 IgG1 Antibodies In Vivo","volume":"117","author":"Wang","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2008236117","article-title":"Fc-Mediated Effector Function Contributes to the In Vivo Antiviral Effect of an HIV Neutralizing Antibody","volume":"117","author":"Asokan","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.05541-11","article-title":"A Panel of IgG1 B12 Variants With Selectively Diminished or Enhanced Affinity for Fcgamma Receptors to Define the Role of Effector Functions in Protection Against HIV","volume":"85","author":"Moldt","year":"2011","journal-title":"J Virol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1080\/14728222.2021.1907343","article-title":"Targeting Fc Effector Function in Vaccine Design","author":"Richardson","year":"2021","journal-title":"Expert Opin Ther Targets"},{"key":"B60","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.chom.2018.12.001","article-title":"HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design","volume":"25","author":"Bricault","year":"2019","journal-title":"Cell Host Microbe"},{"key":"B61","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1128\/JVI.01791-15","article-title":"New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency","volume":"90","author":"Doria-Rose","year":"2016","journal-title":"J Virol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"e1005520","DOI":"10.1371\/journal.ppat.1005520","article-title":"Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection","volume":"12","author":"Wagh","year":"2016","journal-title":"PloS Pathog"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.03136-14","article-title":"Improving Neutralization Potency and Breadth by Combining Broadly Reactive HIV-1 Antibodies Targeting Major Neutralization Epitopes","volume":"89","author":"Kong","year":"2015","journal-title":"J Virol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"e1006860","DOI":"10.1371\/journal.ppat.1006860","article-title":"Potential of Conventional & Bispecific Broadly Neutralizing Antibodies for Prevention of HIV-1 Subtype A, C & D Infections","volume":"14","author":"Wagh","year":"2018","journal-title":"PloS Pathog"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1617789113","article-title":"Paired Quantitative and Qualitative Assessment of the Replication-Competent HIV-1 Reservoir and Comparison With Integrated Proviral DNA","volume":"113","author":"Lorenzi","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/nature18929","article-title":"HIV-1 Antibody 3BNC117 Suppresses Viral Rebound in Humans During Treatment Interruption","volume":"535","author":"Scheid","year":"2016","journal-title":"Nature"},{"key":"B67","doi-asserted-by":"publisher","first-page":"e1005789","DOI":"10.1371\/journal.pcbi.1005789","article-title":"Prediction of HIV-1 Sensitivity to Broadly Neutralizing Antibodies Shows a Trend Towards Resistance Over Time","volume":"13","author":"Hake","year":"2017","journal-title":"PloS Comput Biol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"14696","DOI":"10.1038\/s41598-019-50635-w","article-title":"Accurate Prediction for Antibody Resistance of Clinical HIV-1 Isolates","volume":"9","author":"Rawi","year":"2019","journal-title":"Sci Rep"},{"key":"B69","doi-asserted-by":"publisher","first-page":"e1006952","DOI":"10.1371\/journal.pcbi.1006952","article-title":"Prediction of VRC01 Neutralization Sensitivity by HIV-1 Gp160 Sequence Features","volume":"15","author":"Magaret","year":"2019","journal-title":"PloS Comput Biol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2019.07.009","article-title":"Framework Mutations of the 10-1074 bnAb Increase Conformational Stability, Manufacturability, and Stability While Preserving Full Neutralization Activity","volume":"109","author":"Kerwin","year":"2020","journal-title":"J Pharm Sci"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2018.08.012","article-title":"Coformulation of Broadly Neutralizing Antibodies 3BNC117 and PGT121: Analytical Challenges During Preformulation Characterization and Storage Stability Studies","volume":"107","author":"Patel","year":"2018","journal-title":"J Pharm Sci"},{"key":"B72","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3390\/antib9030036","article-title":"Characterization of Co-Formulated High-Concentration Broadly Neutralizing Anti-HIV-1 Monoclonal Antibodies for Subcutaneous Administration","volume":"9","author":"Sharma","year":"2020","journal-title":"Antibodies (Basel)"},{"key":"B73","doi-asserted-by":"publisher","first-page":"e1002493","DOI":"10.1371\/journal.pmed.1002493","article-title":"Safety and Pharmacokinetics of the Fc-Modified HIV-1 Human Monoclonal Antibody VRC01LS: A Phase 1 Open-Label Clinical Trial in Healthy Adults","volume":"15","author":"Gaudinski","year":"2018","journal-title":"PloS Med"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2031738","article-title":"Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition","volume":"384","author":"Corey","year":"2021","journal-title":"N Engl J Med"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(19)30181-X","article-title":"Safety and Pharmacokinetics of Broadly Neutralising Human Monoclonal Antibody VRC07-523LS in Healthy Adults: A Phase 1 Dose-Escalation Clinical Trial","volume":"6","author":"Gaudinski","year":"2019","journal-title":"Lancet HIV"},{"key":"B76","volume-title":"Safety and Single-Dose Pharmacokinetics of VRC07-523ls Administered via Different Routes and Doses","author":"Walsh","year":"2021"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1038\/nature14411","article-title":"Viraemia Suppressed in HIV-1-Infected Humans by Broadly Neutralizing Antibody 3BNC117","volume":"522","author":"Caskey","year":"2015","journal-title":"Nature"},{"key":"B78","volume-title":"Preclinical to Clinical: 3BNC117 and 10-1074 bNAb Combination for HIV Prophylaxis","author":"Caskey","year":"2021"},{"key":"B79","volume-title":"A Phase I Dose-Escalation Trial of Human Monoclonal Antibody N6LS in Healthy Adults","author":"Widge","year":"2020"},{"key":"B80","volume-title":"Review of Bnabs in Clinical Development","author":"Koup","year":"2018"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(19)30003-7","article-title":"Adeno-Associated Virus Vectored Immunoprophylaxis to Prevent HIV in Healthy Adults: A Phase 1 Randomised Controlled Trial","volume":"6","author":"Priddy","year":"2019","journal-title":"Lancet HIV"},{"key":"B82","doi-asserted-by":"publisher","first-page":"e042247","DOI":"10.1136\/bmjopen-2020-042247","article-title":"Assessing the Safety and Pharmacokinetics of the Anti-HIV Monoclonal Antibody CAP256V2LS Alone and in Combination With VRC07-523LS and PGT121 in South African Women: Study Protocol for the First-in-Human CAPRISA 012B Phase I Clinical Trial","volume":"10","author":"Mahomed","year":"2020","journal-title":"BMJ Open"},{"key":"B83","volume-title":"Therapeutic Activity of PGT121 Monoclonal Antibody in HIV-Infected Adults","author":"Stephenson","year":"2019"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4268","article-title":"Antibody 10-1074 Suppresses Viremia in HIV-1-Infected Individuals","volume":"23","author":"Caskey","year":"2017","journal-title":"Nat Med"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200201250-00012","article-title":"A Phase I Trial With Two Human Monoclonal Antibodies (hMAb 2F5, 2G12) Against HIV-1","volume":"16","author":"Armbruster","year":"2002","journal-title":"AIDS"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1126\/science.1192819","article-title":"Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01","volume":"329","author":"Zhou","year":"2010","journal-title":"Science"},{"key":"B87","doi-asserted-by":"publisher","first-page":"319ra206","DOI":"10.1126\/scitranslmed.aad5752","article-title":"Virologic Effects of Broadly Neutralizing Antibody VRC01 Administration During Chronic HIV-1 Infection","volume":"7","author":"Lynch","year":"2015","journal-title":"Sci Transl Med"},{"key":"B88","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/cei.12692","article-title":"Safety, Pharmacokinetics and Neutralization of the Broadly Neutralizing HIV-1 Human Monoclonal Antibody VRC01 in Healthy Adults","volume":"182","author":"Ledgerwood","year":"2015","journal-title":"Clin Exp Immunol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"e1002435","DOI":"10.1371\/journal.pmed.1002435","article-title":"Safety, Pharmacokinetics, and Immunological Activities of Multiple Intravenous or Subcutaneous Doses of an Anti-HIV Monoclonal Antibody, VRC01, Administered to HIV-Uninfected Adults: Results of a Phase 1 Randomized Trial","volume":"14","author":"Mayer","year":"2017","journal-title":"PloS Med"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1608243","article-title":"Effect of HIV Antibody VRC01 on Viral Rebound After Treatment Interruption","volume":"375","author":"Bar","year":"2016","journal-title":"N Engl J Med"},{"key":"B91","doi-asserted-by":"publisher","first-page":"e0219142","DOI":"10.1371\/journal.pone.0219142","article-title":"Safety, Pharmacokinetics, and Immunogenicity of the Combination of the Broadly Neutralizing Anti-HIV-1 Antibodies 3BNC117 and 10-1074 in Healthy Adults: A Randomized, Phase 1 Study","volume":"14","author":"Cohen","year":"2019","journal-title":"PloS One"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02213-14","article-title":"Enhanced Potency of a Broadly Neutralizing HIV-1 Antibody In Vitro Improves Protection Against Lentiviral Infection In Vivo","volume":"88","author":"Rudicell","year":"2014","journal-title":"J Virol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1038\/nature13612","article-title":"Enhanced Neonatal Fc Receptor Function Improves Protection Against Primate SHIV Infection","volume":"514","author":"Ko","year":"2014","journal-title":"Nature"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.1601","article-title":"Enhanced Antibody Half-Life Improves In Vivo Activity","volume":"28","author":"Zalevsky","year":"2010","journal-title":"Nat Biotechnol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.05.024","article-title":"Engineered Bispecific Antibodies With Exquisite HIV-1-Neutralizing Activity","volume":"165","author":"Huang","year":"2016","journal-title":"Cell"},{"key":"B96","doi-asserted-by":"publisher","first-page":"e1003342","DOI":"10.1371\/journal.ppat.1003342","article-title":"Broadly Neutralizing Antibody PGT121 Allosterically Modulates CD4 Binding via Recognition of the HIV-1 Gp120 V3 Base and Multiple Surrounding Glycans","volume":"9","author":"Julien","year":"2013","journal-title":"PloS Pathog"},{"key":"B97","doi-asserted-by":"publisher","first-page":"236ra263","DOI":"10.1126\/scitranslmed.3008104","article-title":"Promiscuous Glycan Site Recognition by Antibodies to the High-Mannose Patch of Gp120 Broadens Neutralization of HIV","volume":"6","author":"Sok","year":"2014","journal-title":"Sci Transl Med"},{"key":"B98","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.cell.2014.09.009","article-title":"Structural Evolution of Glycan Recognition by a Family of Potent HIV Antibodies","volume":"159","author":"Garces","year":"2014","journal-title":"Cell"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1217207109","article-title":"Complex-Type N-Glycan Recognition by Potent Broadly Neutralizing HIV Antibodies","volume":"109","author":"Mouquet","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1415789111","article-title":"Recombinant HIV Envelope Trimer Selects for Quaternary-Dependent Antibodies Targeting the Trimer Apex","volume":"111","author":"Sok","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"B101","doi-asserted-by":"publisher","first-page":"e1954","DOI":"10.1371\/journal.pone.0001954","article-title":"Establishing a Cohort at High Risk of HIV Infection in South Africa: Challenges and Experiences of the CAPRISA 002 Acute Infection Study","volume":"3","author":"van Loggerenberg","year":"2008","journal-title":"PloS One"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3963","article-title":"Viral Variants That Initiate and Drive Maturation of V1V2-Directed HIV-1 Broadly Neutralizing Antibodies","volume":"21","author":"Bhiman","year":"2015","journal-title":"Nat Med"},{"key":"B103","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.chom.2018.09.001","article-title":"HIV Superinfection Drives De Novo Antibody Responses and Not Neutralization Breadth","volume":"24","author":"Sheward","year":"2018","journal-title":"Cell Host Microbe"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1038\/nature11544","article-title":"Broad and Potent Neutralization of HIV-1 by a Gp41-Specific Human Antibody","volume":"491","author":"Huang","year":"2012","journal-title":"Nature"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.03246-15","article-title":"Optimization of the Solubility of HIV-1-Neutralizing Antibody 10E8 Through Somatic Variation and Structure-Based Design","volume":"90","author":"Kwon","year":"2016","journal-title":"J Virol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1126\/science.aap8131","article-title":"Broadly Neutralizing Antibodies to Prevent HIV-1","volume":"358","author":"Cohen","year":"2017","journal-title":"Science"},{"key":"B107","doi-asserted-by":"publisher","first-page":"20160001","DOI":"10.1515\/scid-2016-0001","article-title":"Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-Of-Concept Efficacy Trials","volume":"9","author":"Gilbert","year":"2017","journal-title":"Stat Commun Infect Dis"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002639","article-title":"Feasibility and Successful Enrollment in a Proof-Of-Concept HIV Prevention Trial of VRC01, a Broadly Neutralizing HIV-1 Monoclonal Antibody","volume":"87","author":"Edupuganti","year":"2021","journal-title":"J Acquir Immune Defic Syndr"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002649","article-title":"A Phase 2b Study to Evaluate the Safety and Efficacy of VRC01 Broadly Neutralizing Monoclonal Antibody in Reducing Acquisition of HIV-1 Infection in Women in Sub-Saharan Africa: Baseline Findings","volume":"87","author":"Mgodi","year":"2021","journal-title":"J Acquir Immune Defic Syndr"},{"key":"B110","doi-asserted-by":"publisher","first-page":"103203","DOI":"10.1016\/j.ebiom.2020.103203","article-title":"Pharmacokinetics and Predicted Neutralisation Coverage of VRC01 in HIV-Uninfected Participants of the Antibody Mediated Prevention (AMP) Trials","volume":"64","author":"Huang","year":"2021","journal-title":"EBioMedicine"},{"key":"B111","volume-title":"Infusion Reactions in the Phase 2b Antibody Mediated Prevention (AMP) Studies","author":"Takuva","year":"2021"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908492","article-title":"Vaccination With ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand","volume":"361","author":"Rerks-Ngarm","year":"2009","journal-title":"N Engl J Med"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01883-17","article-title":"Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies Against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells","volume":"92","author":"Cohen","year":"2018","journal-title":"J Virol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1101\/2020.09.24.310938","article-title":"Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies Against Primary African Isolates","volume":"95","author":"Lorenzi","year":"2020","journal-title":"J Virol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0186-4","article-title":"Safety and Antiviral Activity of Combination HIV-1 Broadly Neutralizing Antibodies in Viremic Individuals","volume":"24","author":"Bar-On","year":"2018","journal-title":"Nat Med"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0531-2","article-title":"Combination Therapy With Anti-HIV-1 Antibodies Maintains Viral Suppression","volume":"561","author":"Mendoza","year":"2018","journal-title":"Nature"},{"key":"B117","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.chom.2019.09.016","article-title":"Structural Basis for Broad HIV-1 Neutralization by the MPER-Specific Human Broadly Neutralizing Antibody Ln01","volume":"26","author":"Pinto","year":"2019","journal-title":"Cell Host Microbe"},{"key":"B118","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1016\/j.cell.2018.03.061","article-title":"Identification of Near-Pan-Neutralizing Antibodies Against HIV-1 by Deconvolution of Plasma Humoral Responses","volume":"173","author":"Sajadi","year":"2018","journal-title":"Cell"},{"key":"B119","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.cell.2020.01.010","article-title":"Restriction of HIV-1 Escape by a Highly Broad and Potent Neutralizing Antibody","volume":"180","author":"Schommers","year":"2020","journal-title":"Cell"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1126\/science.1213782","article-title":"Increasing the Potency and Breadth of an HIV Antibody by Using Structure-Based Rational Design","volume":"334","author":"Diskin","year":"2011","journal-title":"Science"},{"key":"B121","doi-asserted-by":"publisher","first-page":"e00159\u201321","DOI":"10.1128\/JVI.00159-21","article-title":"Rational Engraftment of Quaternary-Interactive Acidic Loops for Anti-HIV-1 Antibody Improvement","volume":"95","author":"Liu","year":"2021","journal-title":"J Virol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2020.00176","article-title":"Promise and Progress of an HIV-1 Cure by Adeno-Associated Virus Vector Delivery of Anti-HIV-1 Biologics","volume":"10","author":"Gardner","year":"2020","journal-title":"Front Cell Infect Microbiol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20190287","article-title":"HIV-Specific Humoral Immune Responses by CRISPR\/Cas9-Edited B Cells","volume":"216","author":"Hartweger","year":"2019","journal-title":"J Exp Med"},{"key":"B124","doi-asserted-by":"publisher","first-page":"5850","DOI":"10.1038\/s41467-020-20304-y","article-title":"Vaccine Elicitation of HIV Broadly Neutralizing Antibodies From Engineered B Cells","volume":"11","author":"Huang","year":"2020","journal-title":"Nat Commun"},{"key":"B125","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12977-018-0439-9","article-title":"Engineering Multi-Specific Antibodies Against HIV-1","volume":"15","author":"Padte","year":"2018","journal-title":"Retrovirology"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.04.050","article-title":"Bispecific Anti-HIV-1 Antibodies With Enhanced Breadth and Potency","volume":"165","author":"Bournazos","year":"2016","journal-title":"Cell"},{"key":"B127","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1126\/science.aan8630","article-title":"Trispecific Broadly Neutralizing HIV Antibodies Mediate Potent SHIV Protection in Macaques","volume":"358","author":"Xu","year":"2017","journal-title":"Science"},{"key":"B128","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/nature14264","article-title":"AAV-Expressed Ecd4-Ig Provides Durable Protection From Multiple SHIV Challenges","volume":"519","author":"Gardner","year":"2015","journal-title":"Nature"},{"key":"B129","doi-asserted-by":"publisher","first-page":"e1008083","DOI":"10.1371\/journal.ppat.1008083","article-title":"Hinge Length Contributes to the Phagocytic Activity of HIV-Specific IgG1 and IgG3 Antibodies","volume":"16","author":"Chu","year":"2020","journal-title":"PloS Pathog"},{"key":"B130","doi-asserted-by":"publisher","first-page":"e1008064","DOI":"10.1371\/journal.ppat.1008064","article-title":"IgG3 Enhances Neutralization Potency and Fc Effector Function of an HIV V2-Specific Broadly Neutralizing Antibody","volume":"15","author":"Richardson","year":"2019","journal-title":"PloS Pathog"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M009483200","article-title":"High Resolution Mapping of the Binding Site on Human IgG1 for Fc Gamma RI, Fc Gamma RII, Fc Gamma RIII, and FcRn and Design of IgG1 Variants With Improved Binding to the Fc Gamma R","volume":"276","author":"Shields","year":"2001","journal-title":"J Biol Chem"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1702173114","article-title":"Modulating IgG Effector Function by Fc Glycan Engineering","volume":"114","author":"Li","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"B133","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1080\/22221751.2020.1713707","article-title":"Broadly Neutralizing Antibodies for HIV-1: Efficacies, Challenges and Opportunities","volume":"9","author":"Liu","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"B134","doi-asserted-by":"publisher","first-page":"e1004966","DOI":"10.1371\/journal.ppat.1004966","article-title":"Capacity of Broadly Neutralizing Antibodies to Inhibit HIV-1 Cell-Cell Transmission Is Strain- and Epitope-Dependent","volume":"11","author":"Reh","year":"2015","journal-title":"PloS Pathog"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02425-16","article-title":"Reduced Potency and Incomplete Neutralization of Broadly Neutralizing Antibodies Against Cell-To-Cell Transmission of HIV-1 With Transmitted Founder Envs","volume":"91","author":"Li","year":"2017","journal-title":"J Virol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.712122\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T12:00:10Z","timestamp":1626782410000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.712122\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,20]]},"references-count":135,"alternative-id":["10.3389\/fimmu.2021.712122"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.712122","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,20]]},"article-number":"712122"}}